Voyager faces a challenging outlook, with a negative enterprise value and declining stock amid industry-wide setbacks in AAV gene therapy. The company's lead asset, VY7523, is early in clinical ...
Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback